PRNewsWire
06 Jan 2026, 13:15 UTC · 42w ago
Verdict
Headline takes no side. We score ATOS +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a 'Study May Proceed' letter for Atossa Therapeutics' (Z)-Endoxifen investigational new drug application for metastatic breast cancer.
More positive than 98% of claims this week
(Z)-Endoxifen may offer a new tool for treating metastatic ER+/HER2- breast cancer, including in tumors that have developed resistance to other endocrine therapies.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
(Z)-Endoxifen has demonstrated activity in the oncogenic signaling pathway protein kinase C beta 1 (PKCβ1), distinct from tamoxifen.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company received a 'Study May Proceed' letter from the FDA for its (Z)-endoxifen application, marking an important regulatory milestone.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Insider
13h ago
−76.6%
Price is moving against the score
$2.17 vs $9.26 close before publication (Jan 5) · not market-adjusted
ATOS chart →
